Literature DB >> 14633964

ABC of oral bioavailability: transporters as gatekeepers in the gut.

C G Dietrich1, A Geier, R P J Oude Elferink.   

Abstract

MDR1 (ABCB1), MRP2 (ABCC2), and BCRP (ABCG2) are members of the family of ATP binding cassette (ABC) transporters. These are plasma membrane transporters that are expressed in various organs. The role of MDR1 and MRP2 in the hepatobiliary system is well defined; both contribute to bile formation by transport of drugs, toxins, and waste products across the canalicular membrane. As they transport exogenous and endogenous substances, they reduce the body load of potentially harmful compounds. The role of ABCG2, which is also expressed in the canalicular membrane of hepatocytes, has not yet been fully characterised. All three proteins are also expressed in the apical membrane of enterocytes where they probably control oral availability of many substances. This important "gatekeeper" function of ABC transporters has been recognised recently and is currently under further investigation. Expression and activity of these transporters in the gut may differ between individuals, due to genetic polymorphisms or pathological conditions. This will lead to individual differences in bioavailability of different drugs, toxins, and (food derived) carcinogens. Recent information on substrates, transport mechanisms, function, and regulation of expression of MDR1, MRP2, and BCRP in different species is summarised in this review.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14633964      PMCID: PMC1773875          DOI: 10.1136/gut.52.12.1788

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  108 in total

1.  Inhibition of P-glycoprotein transport function by grapefruit juice psoralen.

Authors:  E J Wang; C N Casciano; R P Clement; W W Johnson
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

2.  Up-regulation of transporters of the MRP family by drugs and toxins.

Authors:  D Schrenk; P R Baus; N Ermel; C Klein; B Vorderstemann; H M Kauffmann
Journal:  Toxicol Lett       Date:  2001-03-31       Impact factor: 4.372

Review 3.  Cytochromes P450 and metabolism of xenobiotics.

Authors:  P Anzenbacher; E Anzenbacherová
Journal:  Cell Mol Life Sci       Date:  2001-05       Impact factor: 9.261

4.  The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity.

Authors:  R E Watkins; G B Wisely; L B Moore; J L Collins; M H Lambert; S P Williams; T M Willson; S A Kliewer; M R Redinbo
Journal:  Science       Date:  2001-06-14       Impact factor: 47.728

5.  Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR.

Authors:  I Dussault; M Lin; K Hollister; E H Wang; T W Synold; B M Forman
Journal:  J Biol Chem       Date:  2001-07-20       Impact factor: 5.157

Review 6.  Regulation of biliary drug efflux pump expression by hormones and xenobiotics.

Authors:  O Fardel; L Payen; A Courtois; L Vernhet; V Lecureur
Journal:  Toxicology       Date:  2001-10-05       Impact factor: 4.221

7.  Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation.

Authors:  T Hashida; S Masuda; S Uemoto; H Saito; K Tanaka; K Inui
Journal:  Clin Pharmacol Ther       Date:  2001-05       Impact factor: 6.875

8.  Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin.

Authors:  A Geick; M Eichelbaum; O Burk
Journal:  J Biol Chem       Date:  2001-01-31       Impact factor: 5.157

9.  Identification of functionally variant MDR1 alleles among European Americans and African Americans.

Authors:  R B Kim; B F Leake; E F Choo; G K Dresser; S V Kubba; U I Schwarz; A Taylor; H G Xie; J McKinsey; S Zhou; L B Lan; J D Schuetz; E G Schuetz; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  2001-08       Impact factor: 6.875

10.  A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.

Authors:  P Perego; M De Cesare; P De Isabella; N Carenini; G Beggiolin; G Pezzoni; M Palumbo; L Tartaglia; G Pratesi; C Pisano; P Carminati; G L Scheffer; F Zunino
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

View more
  53 in total

Review 1.  Efflux transporters as a novel herbivore countermechanism to plant chemical defenses.

Authors:  Jennifer S Sorensen; M Denise Dearing
Journal:  J Chem Ecol       Date:  2006-05-23       Impact factor: 2.626

Review 2.  The stability of ecosystems: a brief overview of the paradox of enrichment.

Authors:  Shovonlal Roy; J Chattopadhyay
Journal:  J Biosci       Date:  2007-03       Impact factor: 1.826

Review 3.  Drug transporters in pharmacokinetics.

Authors:  Ernst Petzinger; Joachim Geyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-11       Impact factor: 3.000

4.  LXR alpha transactivates mouse organic solute transporter alpha and beta via IR-1 elements shared with FXR.

Authors:  Masae Okuwaki; Tappei Takada; Yuki Iwayanagi; Saori Koh; Yoshiaki Kariya; Hiroshi Fujii; Hiroshi Suzuki
Journal:  Pharm Res       Date:  2006-12-20       Impact factor: 4.200

5.  Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist.

Authors:  Martine Gehin; Patricia N Sidharta; Carmela Gnerre; Alexander Treiber; Atef Halabi; Jasper Dingemanse
Journal:  Eur J Clin Pharmacol       Date:  2014-10-18       Impact factor: 2.953

Review 6.  ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.

Authors:  Maryam Hosseini Hasanabady; Fatemeh Kalalinia
Journal:  J Biosci       Date:  2016-06       Impact factor: 1.826

7.  Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux.

Authors:  Svitlana Igel; Siegfried Drescher; Thomas Mürdter; Ute Hofmann; Georg Heinkele; Heike Tegude; Hartmut Glaeser; Stefanie S Brenner; Andrew A Somogyi; Taher Omari; Christian Schäfer; Michel Eichelbaum; Martin F Fromm
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

8.  Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats.

Authors:  Hani Al-Salami; Grant Butt; Ian Tucker; Ranko Skrbic; Svetlana Golocorbin-Kon; Momir Mikov
Journal:  Arch Drug Inf       Date:  2008-07

9.  BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure.

Authors:  J M Day; P A Foster; H J Tutill; S P Newman; Y T Ho; M P Leese; B V L Potter; M J Reed; A Purohit
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

10.  Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study.

Authors:  Vibeke Andersen; Mette Ostergaard; Jane Christensen; Kim Overvad; Anne Tjønneland; Ulla Vogel
Journal:  BMC Cancer       Date:  2009-11-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.